Management of Overactive Bladder
http://www.100md.com
《新英格兰医药杂志》
Overactive bladder is a symptom complex that includes urinary urgency with or without urge incontinence, urinary frequency (voiding eight or more times in a 24-hour period), and nocturia (awakening two or more times at night to void).1,2,3 The International Continence Society classifies overactive bladder as a syndrome for which no precise cause has been identified, with local abnormalities ruled out by diagnostic evaluation.4,5 This review extends beyond the International Continence Society's current definition of overactive bladder, since a broader approach to this syndrome is essential for optimal management.6,7
Because overactive bladder is a recently defined syndrome, its prevalence and natural history have not been well studied.8 In a telephone survey of 16,776 adults who were 40 years of age or older in Europe, 16 percent of men and 17 percent of women reported syndromes suggestive of overactive bladder. The prevalence was 3 percent among men 40 to 44 years of age, 9 percent among women 40 to 44 years of age, 42 percent among men 75 years of age or older, and 31 percent among women 75 years of age or older.9 Similar data on the prevalence of overactive bladder have been reported in the United States.10
Patients with symptoms of overactive bladder tend to curtail their participation in social activities and to isolate themselves and are predisposed to depression. Nocturia is associated with sleep disruption, which decreases the quality of life.11,12,13,14 Postmenopausal women with urge incontinence have a substantially higher risk of falling and sustaining a fracture than women without urge incontinence.15 The costs of overactive bladder are probably high but have not been studied systematically. The total costs of urinary incontinence in the United States in 1995 were estimated to be approximately $26 billion. A substantial proportion of this cost is attributable to urge incontinence, one of the cardinal symptoms of overactive bladder.16
Pathophysiology
The symptoms of overactive bladder have many potential causes and contributing factors (Table 1).1,2,3 Urination involves the higher cortex of the brain; the pons; the spinal cord; the peripheral autonomic, somatic, and sensory afferent innervation of the lower urinary tract; and the anatomical components of the lower urinary tract itself. Disorders of any of these structures may contribute to the symptoms of overactive bladder. The normal bladder functions like a compliant balloon as it fills, with pressure remaining lower than urethral resistance. With the initiation of normal urination, urethral resistance decreases and a phasic contraction of the detrusor muscle empties the bladder (Figure 1A). The symptoms of overactive bladder are usually associated with involuntary contractions of the detrusor muscle (Figure 1B). Overactivity of the detrusor muscle, whether neurogenic or idiopathic, can result in urgency or urge incontinence, depending on the response of the sphincter.17 Detrusor overactivity may also have a myogenic origin.18 Detrusor contractions can be weak as a result of impaired contractibility. Urodynamic testing indicates that up to half of elderly patients with detrusor overactivity empty less than one third of their bladder contents with an involuntary bladder contraction19; incomplete emptying can contribute to urinary frequency by lowering the functional capacity of the bladder.
Table 1. Conditions That Can Cause or Contribute to Symptoms of Overactive Bladder.
Figure 1. Normal Voiding Physiology (Panel A) and Involuntary Detrusor Contraction Commonly Associated with Symptoms of Overactive Bladder (Panel B).
Normally, as bladder volume increases, the detrusor muscle functions like a compliant balloon and maintains a low intravesicular pressure (less than 10 cm of water) — substantially lower than urethral resistance pressure (Panel A). As bladder volume continues to increase, the activity of the striated muscles of the urethral sphincter increases. At the time of normal voluntary voiding, which generally occurs at a urinary volume of 300 to 400 ml, muscle activity in the sphincter ceases, urethral resistance decreases, and a phasic detrusor contraction empties the bladder. In patients with symptomatic overactive bladder, involuntary bladder contractions can cause urgency and may precipitate urine loss, depending on the response of the sphincter (Panel B). Involuntary contractions may occur at any bladder volume, but they commonly occur at volumes of less than 200 ml. The sphincter-muscle activity depicted in Panel B is a response to the involuntary contraction of the detrusor muscle (as opposed to detrusor–sphincter dyssynergy). Detrusor overactivity can be neurogenic or idiopathic and can be accompanied by urgency or be without sensation.
A variety of efferent and afferent neural pathways, reflexes, and central and peripheral neurotransmitters are involved in urine storage and bladder emptying. The relation among these factors is incompletely understood. The role of central neurotransmitters in the voiding cycle has been studied in animals.20,21,22 Glutamate is an excitatory neurotransmitter in pathways controlling the lower urinary tract. Serotonergic activity facilitates urine storage by enhancing the sympathetic reflex pathway and inhibiting the parasympathetic voiding pathway. Dopaminergic pathways may exert both inhibitory and facilitatory effects on voiding. Dopamine D1 receptors appear to have a role in suppressing bladder activity, whereas dopamine D2 receptors appear to facilitate voiding. Other neurotransmitters, such as -aminobutyric acid and enkephalin, inhibit voiding in animals.
Acetylcholine, which interacts with muscarinic receptors on the detrusor muscle, is the predominant peripheral neurotransmitter responsible for bladder contraction. Of the five known muscarinic subtypes (M1 through M5), M3 appears to be the most clinically relevant in the human bladder.20 Acetylcholine interacts with the M3 receptor, initiating a cascade of events that results in contraction of the detrusor muscle (Figure 2). Data from studies of rat bladders suggest that the M2 receptor may also facilitate bladder contraction by reducing intracellular levels of cyclic adenosine monophosphate.23
Figure 2. Current Concepts of Autonomic Efferent Innervation Contributing to Bladder Contraction and Urine Storage.
In the normal human bladder, acetylcholine is the predominant neurotransmitter that causes bladder contraction. Acetylcholine interacts with M3 muscarinic receptors and activates phospholipase C through coupling with G proteins, which generates inositol triphosphate, which in turn causes the release of calcium from the sarcoplasmic reticulum and the contraction of bladder smooth muscle. M2 receptors may contribute to bladder contraction by inhibiting adenylate cyclase activity and decreasing intracellular cyclic adenosine monophosphate (AMP) levels, which mediate bladder relaxation. In the normal human bladder, only a small proportion of muscle contraction is resistant to atropine. Resistance to atropine most likely results from the interaction of ATP with purinergic receptors, including P2X1 receptors. ATP and other noncholinergically mediated processes may have a more important role in disorders that cause overactive bladder. Stimulation of 3-adrenergic receptors may also lead to relaxation of bladder smooth muscle. Plus signs indicate activation, and minus signs inhibition. Data are from Morrison et al.,20 Yoshimura and Chancellor,21 and Andersson and Hedlund.22
Pathologic states can alter sensitivity to muscarinic stimulation. For example, bladder-outflow obstruction appears to enhance responsiveness to acetylcholine, a phenomenon similar to denervation suprasensitivity.20 Normally, only a small proportion of the bladder contraction is resistant to atropine, probably as a result of the interactions of ATP with purinergic receptors. However, ATP may have a more prominent role in bladder contraction in patients with overactive bladder.20,21,22 Anatomical correlates of detrusor overactivity have also been described. For example, the bladders of patients with detrusor overactivity appear to have abnormal gap junctions between smooth-muscle cells.24,25,26,27,28 Such correlates require further study.
Increasing attention has been paid to the role of sensory afferent nerves in normal voiding and detrusor overactivity.20,21,22,29 During bladder filling, afferent activity from the bladder and urethra reaches the spinal cord predominantly by means of the pelvic nerve. Sensory input during bladder filling results in an increase in sympathetic tone, which inhibits bladder parasympathetic motor nerves, causing contraction of the bladder base and urethra. Adrenergic activity may also cause relaxation of the detrusor muscle through the stimulation of 3-adrenergic receptors (Figure 2). 30 Myelinated A delta sensory fibers respond to passive distention and active contraction of the detrusor muscle. Unmyelinated C sensory fibers have a higher mechanical threshold and respond to a variety of neurotransmitters (Figure 3). C fibers are relatively inactive during normal voiding, but they may have a critical role in symptoms of overactive bladder in patients with neurologic and other disorders. Several types of receptors have been identified on afferent nerves, including vanilloid receptors, which are activated by capsaicin and possibly by endogenous anandamide; purinergic receptors (P2X), which are activated by ATP; neurokinin receptors, which respond to substance P and neurokinin A; and receptors for nerve growth factor (trk-A receptors).20,31 Other substances, including nitric oxide, calcitonin gene–related protein, and brain-derived neurotropic factor, may also have an important role in modulating the sensory afferents in the human detrusor.20,21,22 A better understanding of the complex interplay among these various neurotransmitters and other substances derived from uroepithelium, detrusor-muscle cells, and afferent fibers themselves should yield new and more specific targets for drug treatment of overactive bladder.
Figure 3. Current Concepts of Sensory Innervation of the Bladder.
Myelinated A delta sensory fibers respond predominantly to mechanical stretching of detrusor muscle cells during bladder filling. Unmyelinated C sensory fibers may help trigger the symptoms of overactive bladder in pathologic conditions. C fibers have receptors for a variety of neurotransmitters and substances that can be released from afferent nerves, detrusor smooth muscle, and the uroepithelium. These receptors include vanilloid receptors, which can be stimulated by capsaicin and, possibly, endogenous anandamide; purinergic receptors (P2X2 and P2X3), which are activated by ATP; neurokinin receptors, which are activated by neurokinin A and substance P; and trk-A receptors for nerve growth factor. The nerve growth factor produced by muscle cells, as well as nitrous oxide produced by the uroepithelium, may play key roles in modulating the responsiveness of afferent innervation in the bladder. Data are from Morrison et al.,20 Yoshimura and Chancellor,21 and Andersson and Hedlund.22
Diagnostic Evaluation
Effective treatment of patients with symptoms of overactive bladder necessitates a targeted diagnostic evaluation. Guidelines for the management of urinary incontinence32 and benign prostatic hyperplasia33 are relevant to the evaluation of symptoms of overactive bladder. A focused history that includes information about past genitourinary disorders and other conditions outlined in Table 1 should be elicited from all patients. A symptom index for benign prostatic hypertrophy (recommended by the American Urological Association) or a similar symptom index is helpful to include as part of the evaluation in older men.34,35 A variety of questionnaires regarding lower urinary tract symptoms have also been developed for women.36 In addition, diaries can be helpful in determining the frequency, volume, and pattern of voiding, as well as providing clues to underlying causes and contributing factors.37,38 All patients should undergo a focused physical examination that includes genitourinary, pelvic, and rectal examinations; a clean urine specimen should be obtained to rule out hematuria and infection.
Further evaluation should be considered in selected patients. The presence of residual urine after voiding should be determined in patients with risk factors for urinary retention (diabetes, spinal cord disease, and benign prostatic hypertrophy). This can be accomplished by sterile in-and-out catheterization. A portable ultrasonographic device is available that permits noninvasive identification of clinically significant residual urine (>100 ml), with an accuracy rate of more than 90 percent; it costs approximately $8,000.39 Patients with sterile hematuria or risk factors for bladder cancer should undergo cystoscopy, and their urine should be sent for cytologic analysis. Cystoscopy is also indicated in patients with a history of recurrent urinary tract infection. Although some urologists and gynecologists suggest that all patients in whom symptoms of overactive bladder develop should undergo cystoscopy to rule out carcinoma in situ and other intravesical abnormalities, the cost effectiveness of this approach is uncertain. Because early prostate cancer can cause symptoms of overactive bladder, the possibility of prostate cancer should be assessed.
The role of urodynamic testing in the evaluation of patients with symptoms of overactive bladder is controversial. A noninvasive determination of the urinary flow rate, combined with a measurement of residual urine after voiding, appears to be a sensitive method of ruling out obstruction in older men.40 More complex urodynamic testing may be necessary in patients with nonspecific symptoms and may be a more accurate approach to the diagnosis of obstruction than less invasive testing. Because this test is relatively expensive and invasive, it is recommended only to evaluate symptoms of overactive bladder in cases in which the findings will clearly influence treatment, such as after the failure of initial therapy.1,2,3
Therapy
Optimal therapy for overactive bladder depends on a thorough evaluation, followed by treatment of all the likely causes and contributing factors (Table 1). The genesis of symptoms of overactive bladder is commonly multifactorial, and multimodal therapy that includes nonpharmacologic as well as pharmacologic interventions may be indicated.
Nonpharmacologic Interventions
Various clinical trials suggest that behavioral interventions are efficacious for managing urge and mixed urge–stress incontinence. Educating patients about bladder function, appropriate fluid intake (avoidance of caffeine, maintenance of adequate hydration, and the timing of fluid intake), and managing constipation is important for all patients with overactive bladder. Education may, in fact, underlie the prominent placebo effects (approximately 30 percent improvement in symptoms) demonstrated repeatedly in drug trials for incontinence and overactive bladder. Several randomized, controlled trials, largely involving middle-aged women and women under 75 years of age who had urge or mixed urge–stress incontinence, suggest that cognitively intact, motivated patients have a positive response to pelvic-muscle exercises and "bladder training."41,42,43 Approximately 70 percent of patients have a reduction in the number of episodes of incontinence within two to three months. The long-term effectiveness of these interventions requires further study.
Many patients can be taught pelvic-muscle exercises during a pelvic or rectal examination or can learn them with the use of simple educational tools such as an audiotape or a booklet.42 A substantial proportion of older patients benefit from biofeedback-assisted training. "Bladder training" generally refers to a combination of patient education, scheduled voiding and urge-suppression techniques, and pelvic-muscle exercises.41 For some patients with cognitive impairment, limited mobility, or both, the use of toileting-assistance protocols such as prompted voiding can be very helpful in the management of overactive bladder.44 All these behavioral interventions can also be effective adjuncts to drug therapy.
Some patients with severe symptoms of overactive bladder that are refractory to proven behavioral treatment may benefit from other nonpharmacologic interventions. A wide variety of highly absorbent pads and undergarments are available that can be effective and acceptable in selected patients with refractory symptoms in order to maintain "social continence" and good perineal hygiene.45,46 Only limited evidence of efficacy is available regarding more invasive interventions. Electrical stimulation delivered by vaginal or rectal probes can be helpful in teaching some patients the proper use of pelvic muscles (an approach similar to biofeedback), and lower-frequency stimulation can inhibit bladder contraction.47 Sacral neuromodulation by means of implantable stimulators is used in selected patients with severe neurogenic detrusor overactivity.48 Magnetic stimulation has also been approved for the treatment of incontinence, but this requires multiple visits to a facility that has the stimulation equipment. Surgical procedures, including motor-nerve ablation and augmentation cystoplasty, are used only in patients with the most severe symptoms.49,50
Drug Therapy
Many classes of drugs have been studied or proposed for the treatment of symptoms of overactive bladder.1,2,3,20,21,22,51 The majority of clinical trials have targeted the symptoms of urinary incontinence, though more recent trials have specifically included subjects with overactive bladder. Several pitfalls limit the quality of many studies. Expert groups have proposed methodologic standards that should improve the science underlying drug therapy of overactive bladder.52,53,54
Table 2 lists drugs currently used to treat symptoms of overactive bladder and notes both evidence of efficacy and recommendations based on the International Consultation on Urological Diseases.7 A recent review summarizes the efficacy of anticholinergic drugs for the treatment of overactive bladder as reported in 32 placebo-controlled trials that included 6800 subjects, over 70 percent of whom were women.57
Table 2. Drugs Used to Treat Symptoms of Overactive Bladder.
All anticholinergic drugs can have bothersome side effects. Although dry mouth is the most common, constipation, gastroesophageal reflux, blurry vision, urinary retention, and cognitive side effects can also occur. Both overactive bladder and dementia are common in older patients. Since various forms of dementia are routinely treated with cholinesterase inhibitors, the potential for adverse cognitive effects and delirium due to antimuscarinic drugs is a particular concern in this population.58,59 Although these drugs have not had major effects on cognition in clinical trials involving relatively healthy older adults, more subtle but functionally important changes could occur. Quantitative electroencephalographic data suggest that oxybutynin has more central nervous system effects than trospium or tolterodine.60 Long-acting anticholinergic agents and newer, more selective antimuscarinic agents should be tested for clinically important cognitive side effects, especially in older patients.
Among the anticholinergic agents, only oxybutynin, propiverine, tolterodine, and trospium (Table 2) have the highest level of clinical recommendation and evidence of efficacy; oxybutynin and tolterodine have been studied most extensively. Oxybutynin is a nonselective antimuscarinic agent that relaxes bladder muscles and has local anesthetic activity. It is available in immediate and extended-release forms, as well as in a transdermal patch. Immediate-release oxybutynin (usual adult dosage, 5 mg thrice daily) appears to be efficacious for the treatment of neurogenic and non-neurogenic overactivity of the detrusor muscle with urge incontinence. Given in this formulation, oxybutynin has led to a clinically significant improvement, defined as a reduction in incontinence episodes by more than 50 percent, in approximately 60 to 80 percent of study subjects.21,32,51,61 The efficacy of immediate-release oxybutynin has been limited by antimuscarinic side effects of the parent drug and its active metabolite (N-desethyloxybutynin); dry mouth, for example, is reported in up to two thirds of subjects in some clinical trials. Generic immediate-release oxybutynin is relatively inexpensive and may be useful for patients whose symptoms are best managed by a short-acting drug (e.g., symptoms that are bothersome only when the patient is away from home or at night).
A once-daily controlled-release formulation of oxybutynin appears to have the same beneficial effects as immediate-release oxybutynin, with fewer side effects — a benefit ascribed to the more constant levels of the parent drug and, possibly, a lower rate of conversion to the active metabolite in the stomach and small intestine.62 Most studies of controlled-release oxybutynin have reported a reduction in episodes of urge incontinence by approximately 70 percent.43,63,64,65,66 A transdermal oxybutynin patch is also available that is as efficacious as immediate-release oxybutynin but with half the incidence of dry mouth.67,68 In one placebo-controlled trial, the patch caused local skin erythema in more than half the subjects (3 percent of cases were severe) and was associated with pruritus in up to 17 percent.68
Tolterodine is a muscarinic antagonist that is available in short-acting (twice-daily) and long-acting (once-daily) preparations. Both forms have had statistically and clinically significant effects on symptoms of overactive bladder in multiple, randomized, controlled clinical trials.69,70,71,72,73,74,75,76,77 Side effects are similar to those of short-acting oxybutynin, with dry mouth in 20 to 25 percent of patients, and the rates of discontinuation due to side effects are similar to those for placebo (5 to 6 percent). Tolterodine appears to be equally efficacious in old and young subjects and was well tolerated in one trial involving patients who were living in nursing homes.75,76,78 Two published studies, both industry-sponsored, have compared the long-acting forms of oxybutynin and tolterodine. In one study, participating medical practices were randomized,77 and in the other, women (mean age, 60 years) were randomly assigned to receive one or the other of these agents.79 The results of both trials suggest that the drugs have similar efficacy and effectiveness. In addition, both oxybutynin and tolterodine appear to be effective when combined with various types of behavioral interventions.78,80,81,82
Randomized, controlled trials indicate that propiverine and trospium are effective for the treatment of urge incontinence and have fewer side effects than short-acting oxybutynin.83,84,85,86 Neither drug is currently available in the United States (trospium is being evaluated in clinical trials in the United States). Though hyoscyamine, like short-acting oxybutynin, may be useful for some patients with intermittent symptoms or under specific circumstances, it can be associated with prominent side effects. Propantheline has proven efficacy for the treatment of urge incontinence,32,87,88 but the need for multiple daily doses and the relatively high incidence of side effects are drawbacks. Imipramine, a tricyclic antidepressant with both anticholinergic and alpha-adrenergic effects and, possibly, a central effect on voiding reflexes, has been recommended for mixed urge–stress incontinence, which is common among older women with overactive bladder. Imipramine can cause postural hypotension and cardiac-conduction abnormalities and thus must be used carefully.
Postmenopausal women with symptoms of overactive bladder are commonly treated with oral or topical estrogen, but few data document the efficacy of these agents.89,90,91,92 Among men, symptoms of overactive bladder overlap with those of benign prostatic hypertrophy.93,94,95 In clinical practice, the approach to men with symptoms of overactive bladder depends on several factors, such as the degree to which specific symptoms bother the patient, the patient's preferences, evaluation of the risk–benefit ratio, and the physician's bias. Treatment decisions are further complicated by the fact that complex urodynamic studies are required to rule out bladder-outlet obstruction as a cause. Men with isolated symptoms of overactive bladder — in whom prostate cancer and obstruction have been ruled out — are often treated initially with alpha-adrenergic blockers (alpha-blockers). It is difficult to determine the efficacy of these drugs for overactive bladder, because the outcomes of most clinical trials have been based on composite scores that include symptoms of both overactive bladder and obstruction.96,97,98,99,100,101,102 Symptoms of overactive bladder tend to decrease with alpha-blocker therapy, but less so than do symptoms of obstruction.102,103 Because alpha-blockers can cause postural hypotension, they require a gradual titration of the dose and must be used carefully, especially in patients who are already taking antihypertensive agents.93,100,101,102
Men who neither tolerate nor have a response to alpha-blockers and who are not candidates for surgical intervention may benefit from a trial of an anticholinergic agent, provided they are carefully monitored for the development of urinary retention. Further research is needed to determine the optimal use of alpha-blockers and anticholinergic drugs — alone, together, or combined with behavioral therapy — as a treatment for overactive bladder in men.
Treatment of nocturia, the most bothersome symptom of overactive bladder for many patients of both sexes, depends on the primary underlying cause or causes — detrusor overactivity, nocturnal polyuria, a primary sleep disorder, or some combination of these conditions.104,105 Nocturia that is primarily related to detrusor overactivity can be treated with an anticholinergic agent. Nocturnal polyuria related to volume overload (e.g., venous insufficiency or congestive heart failure with peripheral edema) may respond to a small dose of a rapid-acting diuretic taken in the late afternoon. Oral and intranasal preparations of desmopressin are approved for use in children with nocturnal enuresis.
Data supporting an association among nocturnal polyuria, nocturia, abnormal diurnal responsiveness to vasopressin, and levels of endogenous arginine vasopressin in adults are limited and conflicting.106,107,108,109 However, two randomized, controlled trials suggest that orally administered desmopressin can reduce nocturia in both women (mean age, approximately 57 years)110 and men (mean age, approximately 65 years).111 Both trials used a three-week run-in dose-titration design (0.1 to 0.4 mg), during which approximately one third of the patients were excluded. Among patients with some responsiveness and ability to tolerate desmopressin during the dose-titration phase, one third of the women and the men had at least a 50 percent reduction in the number of nighttime voiding episodes (as compared with 3 percent of patients in the placebo group) and a significant increase in the duration of sleep before their first nighttime voiding during the three-week double-blind phase. Side effects were mild; hyponatremia occurred in approximately 5 percent of patients but only during the three-week dose-titration phase. On the basis of these data, oral desmopressin has been approved for the treatment of nocturia in several countries in Europe, but it is not yet approved for this indication in the United States.
Because of their mechanisms of action, several classes of drugs used for other conditions are of potential therapeutic value for patients with overactive bladder, but data from randomized, controlled clinical trials are lacking. Such drug classes include calcium-channel blockers, prostaglandin-synthesis inhibitors, dopamine D1–receptor agonists, beta-adrenergic (particularly 3) agonists, and -aminobutyric acid (GABA) agonists (Table 3).20,21,22 For example, pergolide, a D1-receptor agonist, may benefit patients with Parkinson's disease and lower urinary tract symptoms, and baclofen, a GABA agonist, has been used in patients with the detrusor hyperreflexia associated with spinal cord disorders. Direct injection of botulinum toxin into the detrusor muscle, which inhibits acetylcholine at the presynaptic cholinergic junction, appears to ameliorate detrusor hyperreflexia in patients with spinal cord injury112,113; it may have some therapeutic value in selected patients with severe refractory symptoms of overactive bladder. Although currently available beta-agonists have not been shown to be useful for overactive bladder, more selective 3-agonists may have therapeutic value.
Table 3. Examples of Classes of Drugs under Investigation for the Treatment of Symptoms of Overactive Bladder.
There are several promising directions for the development of drugs to treat overactive bladder (Table 3). At least two antimuscarinic drugs (darifenacin and solifenacin) with selective M3-receptor–antagonist actions and, theoretically, fewer systemic anticholinergic side effects than currently available agents are being studied. Oxybutynin has been instilled intravesicularly through a catheter to treat severe overactivity of the detrusor muscle,114 and a bladder pump is being developed that can deliver a constant dose of intravesicular oxybutynin for up to 30 days.21 Such a device may make this method of drug delivery more practical and acceptable and may result in fewer systemic anticholinergic side effects.
Drugs that act by means of potassium-channel transporters to hyperpolarize smooth muscle and decrease spontaneous bladder contractions may be useful for suppressing involuntary bladder contractions without interfering with normal voiding.115 However, first-generation agents in this class have had effects on vascular smooth muscle and can cause hypotension. Duloxetine is an inhibitor of serotonin and norepinephrine that appears to act centrally, increasing tone in the striated smooth muscle of the external urethral sphincter.116 Although it is being studied primarily for the treatment of stress incontinence, duloxetine may also have therapeutic benefits in patients with mixed stress–urge incontinence. Drugs that act on sensory afferent pathways are also being developed and hold promise when used either alone or in combination with other drugs. Capsaicin and resiniferatoxin desensitize C-fiber afferents and have been administered experimentally by the intravesicular route. Resiniferatoxin appears to be more potent and less irritating than capsaicin and may be more useful clinically.55,117,118 Other drugs that block receptors on sensory afferents, such as neurokinin-receptor antagonists (Figure 3), might not cause urinary retention, which can occur with antimuscarinic agents.
Summary
Symptoms of overactive bladder are common, can be distressing, and are associated with serious adverse consequences such as injurious falls. The symptoms may be caused by myriad factors, including disorders of the lower urinary tract, neurologic conditions, behavioral factors such as caffeine intake, and a variety of commonly prescribed drugs. The pathophysiologic process in an individual patient is often multifactorial. Diagnostic evaluation includes a focused history taking, targeted physical examination, and urinalysis. Selected patients should have a post-void residual determination, and some should undergo cystoscopy (such as those with hematuria) or complex urodynamic testing (such as those with urinary retention or neurologic disorders).
Patients with overactive bladder often benefit from supportive measures such as education, changes in fluid intake, and the use of bedside commodes or urinals, especially at night. Behavioral treatments such as pelvic-muscle exercises and bladder training are efficacious and can enhance the benefits of drug therapy. The mainstay of drug therapy is antimuscarinic agents. The two best-studied agents are oxybutynin and tolterodine; both have well-proven efficacy in short- and long-acting forms. The extended-release formulations and the oxybutynin skin patch are generally well tolerated, but all antimuscarinic drugs can have bothersome anticholinergic side effects. The effects of these agents on cognitive function are a particular concern in older adults. Men with symptoms of overactive bladder in association with benign prostatic hyperplasia may benefit from treatment with alpha-blockers. Promising future directions in drug therapy include the development of more specific antimuscarinic agents, new drug-delivery systems, and drugs that affect the sensory innervation of the lower urinary tract.
Source Information
From the Division of Geriatric Medicine and Gerontology, Wesley Woods Center, Center for Health in Aging, Emory University, and the Birmingham/Atlanta Veterans Affairs Geriatric Research Education Clinical Center — both in Atlanta.
Address reprint requests to Dr. Ouslander at the Wesley Woods Center of Emory University, 1841 Clifton Rd., NE, Atlanta, GA 30329, or at jouslan@emory.edu.
References
Abrams P, Wein AJ, eds. The Overactive Bladder: From Basic Science to Clinical Management Consensus Conference. Urology 1997;50:Suppl:1-114.
Abrams P, Wein AJ, eds. Overactive Bladder and Its Treatments Consensus Conference. Urology 2000;55:Suppl:1-84.
Staskin DR, Wein AJ, eds. New perspectives on the overactive bladder. Urology 2002;60:Suppl:1-104.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:179-183.
Blaivas JG. Overactive bladder revisited. Neurourol Urodyn 2002;21:523-523.
Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002.
Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity: a review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003;169:843-848.
Milson I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-766.
Stewart W, Herzog R, Wein A, et al. Prevalence and impact of overactive bladder in the US: results for the NOBLE program. Neurourol Urodyn 2001;20:406-406. abstract.
Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50:Suppl:100-110.
Brown JS, Posner SF, Stewart AL. Urge incontinence: new health-related quality of life measures. J Am Geriatr Soc 1999;47:980-988.
DuBeau CE, Kiely DK, Resnick NM. Quality of life impact of urge incontinence in older persons: a new measure and conceptual structure. J Am Geriatr Soc 1999;47:989-994.
Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc 2000;48:413-416.
Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48:721-725.
Hu T-W. Moore K, Subak L, et al. Economics of incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:3-20.
Fisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J Urol 2003;169:529-534.
Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50:Suppl:57-73.
Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA 1987;257:3076-3081.
Morrison J, Steers WD, Brading AF, et al. Neurophysiology and neuropharmacology. In: Abrams P, Cardoza L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:86-163.
Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002;168:1897-1913.
Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002;605:Suppl 1:13-21.
Hedge S, Choppin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997;120:1409-1418.
Elbadawi A, Hailemariam S, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. VI. Validation and update of diagnostic criteria in 71 detrusor biopsies. J Urol 1997;157:1802-1813.
Elbadawi A, Hailemariam S, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. VII. Prospective ultrastructural/urodynamic evaluation of its natural evolution. J Urol 1997;157:1814-1822.
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. J Urol 1993;150:1650-1656.
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 1993;150:1657-1667.
Tse V, Wills E, Szonyi G, Khadra MH. The application of ultrastructural studies in the diagnosis of bladder dysfunction in a clinical setting. J Urol 2000;163:535-539.
Jung SY, Fraser MO, Ozawa H, et al. Urethral afferent nerve activity affects the micturition reflex: implication for the relationship between stress incontinence and detrusor instability. J Urol 1999;162:204-212.
Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-825.
O'Reilly BA, Kosaka AH, Knight GF, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002;167:157-164.
Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline. No. 2. 1996 update. Rockville, Md.: Agency for Health Care Policy and Research, March 1996. (AHCPR publication no. 96-0682.)
McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guide. No. 8. Rockville, Md.: Agency for Health Care Policy and Research, February 1994. (AHCPR publication no. 94-0582.)
Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57, 1564.
Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms. J Urol 1997;157:885-889.
Graham CW, Dmochowki RR. Questionnaires for women with urinary symptoms. Neurourol Urodyn 2002;21:473-481.
Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988;71:812-817.
Locher JL, Goode PS, Roth DL, Worrell RL, Burgio KL. Reliability assessment of the bladder diary for urinary incontinence in older women. J Gerontol A Biol Sci Med Sci 2001;56:M32-M35.
Marks LS, Dorey FJ, Macairan ML, Park C, deKernion JB. Three-dimensional ultrasound device for rapid determination of bladder volume. Urology 1997;50:341-348.
DuBeau CE, Yalla SV, Resnick NM. Improving the utility of urine flow rate to exclude outlet obstruction in men with voiding symptoms. J Am Geriatr Soc 1998;46:1118-1124.
Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991;265:609-613.
Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002;288:2293-2299.
Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000.
Ouslander JG, Schnelle JF, Uman G, et al. Predictors of successful prompted voiding among incontinent nursing home residents. JAMA 1995;273:1366-1370.
Johnson TM II, Kincade JE, Bernard SL, Busby-Whitehead J, DeFriese GH. Self-care practices used by older men and women to manage urinary incontinence: results from the National Follow-up Survey on Self-Care and Aging. J Am Geriatr Soc 2000;48:894-902.
Johnson TM, Ouslander JG, Uman GC, Schnelle JF. Urinary incontinence treatment preferences in long-term care. J Am Geriatr Soc 2001;49:710-718.
Brubaker L. Electrical stimulation in overactive bladder. Urology 2000;55:Suppl:17-23, 31.
Hohenfellner M, Dahms SE, Matzel K, Thuroff JW. Sacral neuromodulation for treatment of lower urinary tract dysfunction. BJU Int 2000;85:Suppl 3:10-9, 22.
Madersbacher H. Denervation techniques. BJU Int 2000;85:Suppl 3:1-6, 8.
Atala A. New methods of bladder augmentation. BJU Int 2000;85:Suppl 3:24-34, 36.
Anderson K-E, Appell R, Awad S, et al. Pharmacologic treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:481-511.
Blaivas JG, Appell RA, Fantl JA, et al. Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the Urodynamic Society. Neurourol Urodyn 1997;16:145-147.
Fonda D, Resnick NM, Colling J, et al. Outcome measures for research of lower urinary tract dysfunction in frail older people. Neurourol Urodyn 1998;17:273-281.
Payne C, van Kerrebroeck P, Blaivas JG, et al. Research methodology in urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:1047-77.
De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler C. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. J Urol 1997;158:2087-2092.
Levels of evidence and grades of recommendation. Oxford, England: Centre for Evidence-Based Medicine. (Accessed January 27, 2004, at http://www.cebm.net/levels_of_evidence.asp.)
Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841-844.
Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002;50:1165-1166.
Katz IR, Sands LP, Bilker W, DiFillipo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13.
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-644.
Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-262.
Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999;39:289-296.
Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999;161:1809-1812.
Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999;54:420-423.
Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000;85:793-798.
Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-363.
Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-145.
Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-586.
Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-810.
Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997;15:144-151.
Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-289.
Freedman S, Mitcheson HD, Antoci J, Primus G, Chancellor MF, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000;19:83-91.
Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-421.
Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-1456.
Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-705.
Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807.
Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin 2002;18:177-184.
Ouslander J, Maloney C, Grasela T, Rogers L, Walawander C. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc 2001;2:207-214.
Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-695.
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48:370-374.
Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995;43:610-617.
Mattiasson A, Blaakaer J, H?ye K, Wein AJ, Tolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003;91:54-60.
Mazur D, Wehnert J, Dorschner W, Schubert G, Herfurth G, Alken RG. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence: a multicentre dose-optimizing study. Scand J Urol Nephrol 1995;29:289-294.
Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999;84:646-651.
Madersbacher H, Murtz G. Efficacy, tolerability and safety profile in propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001;19:324-335.
Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995;75:452-456.
Holmes DM, Montz FJ, Stanton SL. Oxybutynin versus propantheline in the management of detrusor instability: a patient-regulated variable dose trial. Br J Obstet Gynaecol 1989;96:607-612.
Thuroff J, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-817.
Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis: first report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83:12-18.
Sultana CJ, Walters MD. Estrogen and urinary incontinence in women. Maturitas 1994;20:129-138.
Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence: the Continence Program for Women Research Group. Obstet Gynecol 1996;88:745-749.
Ouslander JG, Greendale GA, Uman G, Lee C, Paul W, Schnele J. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. J Am Geriatr Soc 2001;49:803-807.
Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 1995;332:99-109.
DuBeau CE, Yalla SV, Resnick NM. Implications of the most bothersome prostatism symptom for clinical care and outcomes research. J Am Geriatr Soc 1995;43:985-992.
Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000;85:Suppl 3:57-68, 70.
Debruyne FM, Witjes WP, Fitzpatrick J, Kirby R, Kirk D, Prezioso D. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1996;30:369-376.
Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.
Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997;157:525-530.
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998;160:1358-1367.
Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257-261.
Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58:717-722.
Johnson TM II, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003;170:145-148.
Weiss JP, Blaivas JG. Nocturia. J Urol 2000;163:5-12.
Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc 2000;48:1321-1329.
Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 1991;229:131-134.
Asplund R, Aberg H. Desmopressin in elderly subjects with increased nocturnal diuresis: a two-month treatment study. Scand J Urol Nephrol 1993;27:77-82.
Ouslander JG, Nasr SZ, Miller M, et al. Arginine vasopressin levels in nursing home residents with nighttime urinary incontinence. J Am Geriatr Soc 1998;46:1274-1279.
Johnson TM II, Miller M, Pillion DJ, Ouslander JG. Arginine vasopressin and nocturnal polyuria in older adults with frequent nighttime voiding. J Urol 2003;170:480-484.
Lose G, Lalos O, Freedman RM, van Kerrebroeck P, Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003;189:1106-1113.
Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002;89:855-862.
Smith CP, Franks ME, Phelan MW, et al. Botulinum toxin A: physiologic and clinical effects on the lower urinary tract. J Urol 2001;165:Suppl:37-37. abstract.
Schurch B, Stohrer M, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-697.
Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989;141:1350-1352.
Martin SW, Radley SC, Chess-Williams R, Korstanje C, Chapple CR. Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle. Br J Urol 1997;80:405-413.
Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000;40:161-167.
Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999;162:3-11.
Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002;168:575-579.(Joseph G. Ouslander, M.D.)
Because overactive bladder is a recently defined syndrome, its prevalence and natural history have not been well studied.8 In a telephone survey of 16,776 adults who were 40 years of age or older in Europe, 16 percent of men and 17 percent of women reported syndromes suggestive of overactive bladder. The prevalence was 3 percent among men 40 to 44 years of age, 9 percent among women 40 to 44 years of age, 42 percent among men 75 years of age or older, and 31 percent among women 75 years of age or older.9 Similar data on the prevalence of overactive bladder have been reported in the United States.10
Patients with symptoms of overactive bladder tend to curtail their participation in social activities and to isolate themselves and are predisposed to depression. Nocturia is associated with sleep disruption, which decreases the quality of life.11,12,13,14 Postmenopausal women with urge incontinence have a substantially higher risk of falling and sustaining a fracture than women without urge incontinence.15 The costs of overactive bladder are probably high but have not been studied systematically. The total costs of urinary incontinence in the United States in 1995 were estimated to be approximately $26 billion. A substantial proportion of this cost is attributable to urge incontinence, one of the cardinal symptoms of overactive bladder.16
Pathophysiology
The symptoms of overactive bladder have many potential causes and contributing factors (Table 1).1,2,3 Urination involves the higher cortex of the brain; the pons; the spinal cord; the peripheral autonomic, somatic, and sensory afferent innervation of the lower urinary tract; and the anatomical components of the lower urinary tract itself. Disorders of any of these structures may contribute to the symptoms of overactive bladder. The normal bladder functions like a compliant balloon as it fills, with pressure remaining lower than urethral resistance. With the initiation of normal urination, urethral resistance decreases and a phasic contraction of the detrusor muscle empties the bladder (Figure 1A). The symptoms of overactive bladder are usually associated with involuntary contractions of the detrusor muscle (Figure 1B). Overactivity of the detrusor muscle, whether neurogenic or idiopathic, can result in urgency or urge incontinence, depending on the response of the sphincter.17 Detrusor overactivity may also have a myogenic origin.18 Detrusor contractions can be weak as a result of impaired contractibility. Urodynamic testing indicates that up to half of elderly patients with detrusor overactivity empty less than one third of their bladder contents with an involuntary bladder contraction19; incomplete emptying can contribute to urinary frequency by lowering the functional capacity of the bladder.
Table 1. Conditions That Can Cause or Contribute to Symptoms of Overactive Bladder.
Figure 1. Normal Voiding Physiology (Panel A) and Involuntary Detrusor Contraction Commonly Associated with Symptoms of Overactive Bladder (Panel B).
Normally, as bladder volume increases, the detrusor muscle functions like a compliant balloon and maintains a low intravesicular pressure (less than 10 cm of water) — substantially lower than urethral resistance pressure (Panel A). As bladder volume continues to increase, the activity of the striated muscles of the urethral sphincter increases. At the time of normal voluntary voiding, which generally occurs at a urinary volume of 300 to 400 ml, muscle activity in the sphincter ceases, urethral resistance decreases, and a phasic detrusor contraction empties the bladder. In patients with symptomatic overactive bladder, involuntary bladder contractions can cause urgency and may precipitate urine loss, depending on the response of the sphincter (Panel B). Involuntary contractions may occur at any bladder volume, but they commonly occur at volumes of less than 200 ml. The sphincter-muscle activity depicted in Panel B is a response to the involuntary contraction of the detrusor muscle (as opposed to detrusor–sphincter dyssynergy). Detrusor overactivity can be neurogenic or idiopathic and can be accompanied by urgency or be without sensation.
A variety of efferent and afferent neural pathways, reflexes, and central and peripheral neurotransmitters are involved in urine storage and bladder emptying. The relation among these factors is incompletely understood. The role of central neurotransmitters in the voiding cycle has been studied in animals.20,21,22 Glutamate is an excitatory neurotransmitter in pathways controlling the lower urinary tract. Serotonergic activity facilitates urine storage by enhancing the sympathetic reflex pathway and inhibiting the parasympathetic voiding pathway. Dopaminergic pathways may exert both inhibitory and facilitatory effects on voiding. Dopamine D1 receptors appear to have a role in suppressing bladder activity, whereas dopamine D2 receptors appear to facilitate voiding. Other neurotransmitters, such as -aminobutyric acid and enkephalin, inhibit voiding in animals.
Acetylcholine, which interacts with muscarinic receptors on the detrusor muscle, is the predominant peripheral neurotransmitter responsible for bladder contraction. Of the five known muscarinic subtypes (M1 through M5), M3 appears to be the most clinically relevant in the human bladder.20 Acetylcholine interacts with the M3 receptor, initiating a cascade of events that results in contraction of the detrusor muscle (Figure 2). Data from studies of rat bladders suggest that the M2 receptor may also facilitate bladder contraction by reducing intracellular levels of cyclic adenosine monophosphate.23
Figure 2. Current Concepts of Autonomic Efferent Innervation Contributing to Bladder Contraction and Urine Storage.
In the normal human bladder, acetylcholine is the predominant neurotransmitter that causes bladder contraction. Acetylcholine interacts with M3 muscarinic receptors and activates phospholipase C through coupling with G proteins, which generates inositol triphosphate, which in turn causes the release of calcium from the sarcoplasmic reticulum and the contraction of bladder smooth muscle. M2 receptors may contribute to bladder contraction by inhibiting adenylate cyclase activity and decreasing intracellular cyclic adenosine monophosphate (AMP) levels, which mediate bladder relaxation. In the normal human bladder, only a small proportion of muscle contraction is resistant to atropine. Resistance to atropine most likely results from the interaction of ATP with purinergic receptors, including P2X1 receptors. ATP and other noncholinergically mediated processes may have a more important role in disorders that cause overactive bladder. Stimulation of 3-adrenergic receptors may also lead to relaxation of bladder smooth muscle. Plus signs indicate activation, and minus signs inhibition. Data are from Morrison et al.,20 Yoshimura and Chancellor,21 and Andersson and Hedlund.22
Pathologic states can alter sensitivity to muscarinic stimulation. For example, bladder-outflow obstruction appears to enhance responsiveness to acetylcholine, a phenomenon similar to denervation suprasensitivity.20 Normally, only a small proportion of the bladder contraction is resistant to atropine, probably as a result of the interactions of ATP with purinergic receptors. However, ATP may have a more prominent role in bladder contraction in patients with overactive bladder.20,21,22 Anatomical correlates of detrusor overactivity have also been described. For example, the bladders of patients with detrusor overactivity appear to have abnormal gap junctions between smooth-muscle cells.24,25,26,27,28 Such correlates require further study.
Increasing attention has been paid to the role of sensory afferent nerves in normal voiding and detrusor overactivity.20,21,22,29 During bladder filling, afferent activity from the bladder and urethra reaches the spinal cord predominantly by means of the pelvic nerve. Sensory input during bladder filling results in an increase in sympathetic tone, which inhibits bladder parasympathetic motor nerves, causing contraction of the bladder base and urethra. Adrenergic activity may also cause relaxation of the detrusor muscle through the stimulation of 3-adrenergic receptors (Figure 2). 30 Myelinated A delta sensory fibers respond to passive distention and active contraction of the detrusor muscle. Unmyelinated C sensory fibers have a higher mechanical threshold and respond to a variety of neurotransmitters (Figure 3). C fibers are relatively inactive during normal voiding, but they may have a critical role in symptoms of overactive bladder in patients with neurologic and other disorders. Several types of receptors have been identified on afferent nerves, including vanilloid receptors, which are activated by capsaicin and possibly by endogenous anandamide; purinergic receptors (P2X), which are activated by ATP; neurokinin receptors, which respond to substance P and neurokinin A; and receptors for nerve growth factor (trk-A receptors).20,31 Other substances, including nitric oxide, calcitonin gene–related protein, and brain-derived neurotropic factor, may also have an important role in modulating the sensory afferents in the human detrusor.20,21,22 A better understanding of the complex interplay among these various neurotransmitters and other substances derived from uroepithelium, detrusor-muscle cells, and afferent fibers themselves should yield new and more specific targets for drug treatment of overactive bladder.
Figure 3. Current Concepts of Sensory Innervation of the Bladder.
Myelinated A delta sensory fibers respond predominantly to mechanical stretching of detrusor muscle cells during bladder filling. Unmyelinated C sensory fibers may help trigger the symptoms of overactive bladder in pathologic conditions. C fibers have receptors for a variety of neurotransmitters and substances that can be released from afferent nerves, detrusor smooth muscle, and the uroepithelium. These receptors include vanilloid receptors, which can be stimulated by capsaicin and, possibly, endogenous anandamide; purinergic receptors (P2X2 and P2X3), which are activated by ATP; neurokinin receptors, which are activated by neurokinin A and substance P; and trk-A receptors for nerve growth factor. The nerve growth factor produced by muscle cells, as well as nitrous oxide produced by the uroepithelium, may play key roles in modulating the responsiveness of afferent innervation in the bladder. Data are from Morrison et al.,20 Yoshimura and Chancellor,21 and Andersson and Hedlund.22
Diagnostic Evaluation
Effective treatment of patients with symptoms of overactive bladder necessitates a targeted diagnostic evaluation. Guidelines for the management of urinary incontinence32 and benign prostatic hyperplasia33 are relevant to the evaluation of symptoms of overactive bladder. A focused history that includes information about past genitourinary disorders and other conditions outlined in Table 1 should be elicited from all patients. A symptom index for benign prostatic hypertrophy (recommended by the American Urological Association) or a similar symptom index is helpful to include as part of the evaluation in older men.34,35 A variety of questionnaires regarding lower urinary tract symptoms have also been developed for women.36 In addition, diaries can be helpful in determining the frequency, volume, and pattern of voiding, as well as providing clues to underlying causes and contributing factors.37,38 All patients should undergo a focused physical examination that includes genitourinary, pelvic, and rectal examinations; a clean urine specimen should be obtained to rule out hematuria and infection.
Further evaluation should be considered in selected patients. The presence of residual urine after voiding should be determined in patients with risk factors for urinary retention (diabetes, spinal cord disease, and benign prostatic hypertrophy). This can be accomplished by sterile in-and-out catheterization. A portable ultrasonographic device is available that permits noninvasive identification of clinically significant residual urine (>100 ml), with an accuracy rate of more than 90 percent; it costs approximately $8,000.39 Patients with sterile hematuria or risk factors for bladder cancer should undergo cystoscopy, and their urine should be sent for cytologic analysis. Cystoscopy is also indicated in patients with a history of recurrent urinary tract infection. Although some urologists and gynecologists suggest that all patients in whom symptoms of overactive bladder develop should undergo cystoscopy to rule out carcinoma in situ and other intravesical abnormalities, the cost effectiveness of this approach is uncertain. Because early prostate cancer can cause symptoms of overactive bladder, the possibility of prostate cancer should be assessed.
The role of urodynamic testing in the evaluation of patients with symptoms of overactive bladder is controversial. A noninvasive determination of the urinary flow rate, combined with a measurement of residual urine after voiding, appears to be a sensitive method of ruling out obstruction in older men.40 More complex urodynamic testing may be necessary in patients with nonspecific symptoms and may be a more accurate approach to the diagnosis of obstruction than less invasive testing. Because this test is relatively expensive and invasive, it is recommended only to evaluate symptoms of overactive bladder in cases in which the findings will clearly influence treatment, such as after the failure of initial therapy.1,2,3
Therapy
Optimal therapy for overactive bladder depends on a thorough evaluation, followed by treatment of all the likely causes and contributing factors (Table 1). The genesis of symptoms of overactive bladder is commonly multifactorial, and multimodal therapy that includes nonpharmacologic as well as pharmacologic interventions may be indicated.
Nonpharmacologic Interventions
Various clinical trials suggest that behavioral interventions are efficacious for managing urge and mixed urge–stress incontinence. Educating patients about bladder function, appropriate fluid intake (avoidance of caffeine, maintenance of adequate hydration, and the timing of fluid intake), and managing constipation is important for all patients with overactive bladder. Education may, in fact, underlie the prominent placebo effects (approximately 30 percent improvement in symptoms) demonstrated repeatedly in drug trials for incontinence and overactive bladder. Several randomized, controlled trials, largely involving middle-aged women and women under 75 years of age who had urge or mixed urge–stress incontinence, suggest that cognitively intact, motivated patients have a positive response to pelvic-muscle exercises and "bladder training."41,42,43 Approximately 70 percent of patients have a reduction in the number of episodes of incontinence within two to three months. The long-term effectiveness of these interventions requires further study.
Many patients can be taught pelvic-muscle exercises during a pelvic or rectal examination or can learn them with the use of simple educational tools such as an audiotape or a booklet.42 A substantial proportion of older patients benefit from biofeedback-assisted training. "Bladder training" generally refers to a combination of patient education, scheduled voiding and urge-suppression techniques, and pelvic-muscle exercises.41 For some patients with cognitive impairment, limited mobility, or both, the use of toileting-assistance protocols such as prompted voiding can be very helpful in the management of overactive bladder.44 All these behavioral interventions can also be effective adjuncts to drug therapy.
Some patients with severe symptoms of overactive bladder that are refractory to proven behavioral treatment may benefit from other nonpharmacologic interventions. A wide variety of highly absorbent pads and undergarments are available that can be effective and acceptable in selected patients with refractory symptoms in order to maintain "social continence" and good perineal hygiene.45,46 Only limited evidence of efficacy is available regarding more invasive interventions. Electrical stimulation delivered by vaginal or rectal probes can be helpful in teaching some patients the proper use of pelvic muscles (an approach similar to biofeedback), and lower-frequency stimulation can inhibit bladder contraction.47 Sacral neuromodulation by means of implantable stimulators is used in selected patients with severe neurogenic detrusor overactivity.48 Magnetic stimulation has also been approved for the treatment of incontinence, but this requires multiple visits to a facility that has the stimulation equipment. Surgical procedures, including motor-nerve ablation and augmentation cystoplasty, are used only in patients with the most severe symptoms.49,50
Drug Therapy
Many classes of drugs have been studied or proposed for the treatment of symptoms of overactive bladder.1,2,3,20,21,22,51 The majority of clinical trials have targeted the symptoms of urinary incontinence, though more recent trials have specifically included subjects with overactive bladder. Several pitfalls limit the quality of many studies. Expert groups have proposed methodologic standards that should improve the science underlying drug therapy of overactive bladder.52,53,54
Table 2 lists drugs currently used to treat symptoms of overactive bladder and notes both evidence of efficacy and recommendations based on the International Consultation on Urological Diseases.7 A recent review summarizes the efficacy of anticholinergic drugs for the treatment of overactive bladder as reported in 32 placebo-controlled trials that included 6800 subjects, over 70 percent of whom were women.57
Table 2. Drugs Used to Treat Symptoms of Overactive Bladder.
All anticholinergic drugs can have bothersome side effects. Although dry mouth is the most common, constipation, gastroesophageal reflux, blurry vision, urinary retention, and cognitive side effects can also occur. Both overactive bladder and dementia are common in older patients. Since various forms of dementia are routinely treated with cholinesterase inhibitors, the potential for adverse cognitive effects and delirium due to antimuscarinic drugs is a particular concern in this population.58,59 Although these drugs have not had major effects on cognition in clinical trials involving relatively healthy older adults, more subtle but functionally important changes could occur. Quantitative electroencephalographic data suggest that oxybutynin has more central nervous system effects than trospium or tolterodine.60 Long-acting anticholinergic agents and newer, more selective antimuscarinic agents should be tested for clinically important cognitive side effects, especially in older patients.
Among the anticholinergic agents, only oxybutynin, propiverine, tolterodine, and trospium (Table 2) have the highest level of clinical recommendation and evidence of efficacy; oxybutynin and tolterodine have been studied most extensively. Oxybutynin is a nonselective antimuscarinic agent that relaxes bladder muscles and has local anesthetic activity. It is available in immediate and extended-release forms, as well as in a transdermal patch. Immediate-release oxybutynin (usual adult dosage, 5 mg thrice daily) appears to be efficacious for the treatment of neurogenic and non-neurogenic overactivity of the detrusor muscle with urge incontinence. Given in this formulation, oxybutynin has led to a clinically significant improvement, defined as a reduction in incontinence episodes by more than 50 percent, in approximately 60 to 80 percent of study subjects.21,32,51,61 The efficacy of immediate-release oxybutynin has been limited by antimuscarinic side effects of the parent drug and its active metabolite (N-desethyloxybutynin); dry mouth, for example, is reported in up to two thirds of subjects in some clinical trials. Generic immediate-release oxybutynin is relatively inexpensive and may be useful for patients whose symptoms are best managed by a short-acting drug (e.g., symptoms that are bothersome only when the patient is away from home or at night).
A once-daily controlled-release formulation of oxybutynin appears to have the same beneficial effects as immediate-release oxybutynin, with fewer side effects — a benefit ascribed to the more constant levels of the parent drug and, possibly, a lower rate of conversion to the active metabolite in the stomach and small intestine.62 Most studies of controlled-release oxybutynin have reported a reduction in episodes of urge incontinence by approximately 70 percent.43,63,64,65,66 A transdermal oxybutynin patch is also available that is as efficacious as immediate-release oxybutynin but with half the incidence of dry mouth.67,68 In one placebo-controlled trial, the patch caused local skin erythema in more than half the subjects (3 percent of cases were severe) and was associated with pruritus in up to 17 percent.68
Tolterodine is a muscarinic antagonist that is available in short-acting (twice-daily) and long-acting (once-daily) preparations. Both forms have had statistically and clinically significant effects on symptoms of overactive bladder in multiple, randomized, controlled clinical trials.69,70,71,72,73,74,75,76,77 Side effects are similar to those of short-acting oxybutynin, with dry mouth in 20 to 25 percent of patients, and the rates of discontinuation due to side effects are similar to those for placebo (5 to 6 percent). Tolterodine appears to be equally efficacious in old and young subjects and was well tolerated in one trial involving patients who were living in nursing homes.75,76,78 Two published studies, both industry-sponsored, have compared the long-acting forms of oxybutynin and tolterodine. In one study, participating medical practices were randomized,77 and in the other, women (mean age, 60 years) were randomly assigned to receive one or the other of these agents.79 The results of both trials suggest that the drugs have similar efficacy and effectiveness. In addition, both oxybutynin and tolterodine appear to be effective when combined with various types of behavioral interventions.78,80,81,82
Randomized, controlled trials indicate that propiverine and trospium are effective for the treatment of urge incontinence and have fewer side effects than short-acting oxybutynin.83,84,85,86 Neither drug is currently available in the United States (trospium is being evaluated in clinical trials in the United States). Though hyoscyamine, like short-acting oxybutynin, may be useful for some patients with intermittent symptoms or under specific circumstances, it can be associated with prominent side effects. Propantheline has proven efficacy for the treatment of urge incontinence,32,87,88 but the need for multiple daily doses and the relatively high incidence of side effects are drawbacks. Imipramine, a tricyclic antidepressant with both anticholinergic and alpha-adrenergic effects and, possibly, a central effect on voiding reflexes, has been recommended for mixed urge–stress incontinence, which is common among older women with overactive bladder. Imipramine can cause postural hypotension and cardiac-conduction abnormalities and thus must be used carefully.
Postmenopausal women with symptoms of overactive bladder are commonly treated with oral or topical estrogen, but few data document the efficacy of these agents.89,90,91,92 Among men, symptoms of overactive bladder overlap with those of benign prostatic hypertrophy.93,94,95 In clinical practice, the approach to men with symptoms of overactive bladder depends on several factors, such as the degree to which specific symptoms bother the patient, the patient's preferences, evaluation of the risk–benefit ratio, and the physician's bias. Treatment decisions are further complicated by the fact that complex urodynamic studies are required to rule out bladder-outlet obstruction as a cause. Men with isolated symptoms of overactive bladder — in whom prostate cancer and obstruction have been ruled out — are often treated initially with alpha-adrenergic blockers (alpha-blockers). It is difficult to determine the efficacy of these drugs for overactive bladder, because the outcomes of most clinical trials have been based on composite scores that include symptoms of both overactive bladder and obstruction.96,97,98,99,100,101,102 Symptoms of overactive bladder tend to decrease with alpha-blocker therapy, but less so than do symptoms of obstruction.102,103 Because alpha-blockers can cause postural hypotension, they require a gradual titration of the dose and must be used carefully, especially in patients who are already taking antihypertensive agents.93,100,101,102
Men who neither tolerate nor have a response to alpha-blockers and who are not candidates for surgical intervention may benefit from a trial of an anticholinergic agent, provided they are carefully monitored for the development of urinary retention. Further research is needed to determine the optimal use of alpha-blockers and anticholinergic drugs — alone, together, or combined with behavioral therapy — as a treatment for overactive bladder in men.
Treatment of nocturia, the most bothersome symptom of overactive bladder for many patients of both sexes, depends on the primary underlying cause or causes — detrusor overactivity, nocturnal polyuria, a primary sleep disorder, or some combination of these conditions.104,105 Nocturia that is primarily related to detrusor overactivity can be treated with an anticholinergic agent. Nocturnal polyuria related to volume overload (e.g., venous insufficiency or congestive heart failure with peripheral edema) may respond to a small dose of a rapid-acting diuretic taken in the late afternoon. Oral and intranasal preparations of desmopressin are approved for use in children with nocturnal enuresis.
Data supporting an association among nocturnal polyuria, nocturia, abnormal diurnal responsiveness to vasopressin, and levels of endogenous arginine vasopressin in adults are limited and conflicting.106,107,108,109 However, two randomized, controlled trials suggest that orally administered desmopressin can reduce nocturia in both women (mean age, approximately 57 years)110 and men (mean age, approximately 65 years).111 Both trials used a three-week run-in dose-titration design (0.1 to 0.4 mg), during which approximately one third of the patients were excluded. Among patients with some responsiveness and ability to tolerate desmopressin during the dose-titration phase, one third of the women and the men had at least a 50 percent reduction in the number of nighttime voiding episodes (as compared with 3 percent of patients in the placebo group) and a significant increase in the duration of sleep before their first nighttime voiding during the three-week double-blind phase. Side effects were mild; hyponatremia occurred in approximately 5 percent of patients but only during the three-week dose-titration phase. On the basis of these data, oral desmopressin has been approved for the treatment of nocturia in several countries in Europe, but it is not yet approved for this indication in the United States.
Because of their mechanisms of action, several classes of drugs used for other conditions are of potential therapeutic value for patients with overactive bladder, but data from randomized, controlled clinical trials are lacking. Such drug classes include calcium-channel blockers, prostaglandin-synthesis inhibitors, dopamine D1–receptor agonists, beta-adrenergic (particularly 3) agonists, and -aminobutyric acid (GABA) agonists (Table 3).20,21,22 For example, pergolide, a D1-receptor agonist, may benefit patients with Parkinson's disease and lower urinary tract symptoms, and baclofen, a GABA agonist, has been used in patients with the detrusor hyperreflexia associated with spinal cord disorders. Direct injection of botulinum toxin into the detrusor muscle, which inhibits acetylcholine at the presynaptic cholinergic junction, appears to ameliorate detrusor hyperreflexia in patients with spinal cord injury112,113; it may have some therapeutic value in selected patients with severe refractory symptoms of overactive bladder. Although currently available beta-agonists have not been shown to be useful for overactive bladder, more selective 3-agonists may have therapeutic value.
Table 3. Examples of Classes of Drugs under Investigation for the Treatment of Symptoms of Overactive Bladder.
There are several promising directions for the development of drugs to treat overactive bladder (Table 3). At least two antimuscarinic drugs (darifenacin and solifenacin) with selective M3-receptor–antagonist actions and, theoretically, fewer systemic anticholinergic side effects than currently available agents are being studied. Oxybutynin has been instilled intravesicularly through a catheter to treat severe overactivity of the detrusor muscle,114 and a bladder pump is being developed that can deliver a constant dose of intravesicular oxybutynin for up to 30 days.21 Such a device may make this method of drug delivery more practical and acceptable and may result in fewer systemic anticholinergic side effects.
Drugs that act by means of potassium-channel transporters to hyperpolarize smooth muscle and decrease spontaneous bladder contractions may be useful for suppressing involuntary bladder contractions without interfering with normal voiding.115 However, first-generation agents in this class have had effects on vascular smooth muscle and can cause hypotension. Duloxetine is an inhibitor of serotonin and norepinephrine that appears to act centrally, increasing tone in the striated smooth muscle of the external urethral sphincter.116 Although it is being studied primarily for the treatment of stress incontinence, duloxetine may also have therapeutic benefits in patients with mixed stress–urge incontinence. Drugs that act on sensory afferent pathways are also being developed and hold promise when used either alone or in combination with other drugs. Capsaicin and resiniferatoxin desensitize C-fiber afferents and have been administered experimentally by the intravesicular route. Resiniferatoxin appears to be more potent and less irritating than capsaicin and may be more useful clinically.55,117,118 Other drugs that block receptors on sensory afferents, such as neurokinin-receptor antagonists (Figure 3), might not cause urinary retention, which can occur with antimuscarinic agents.
Summary
Symptoms of overactive bladder are common, can be distressing, and are associated with serious adverse consequences such as injurious falls. The symptoms may be caused by myriad factors, including disorders of the lower urinary tract, neurologic conditions, behavioral factors such as caffeine intake, and a variety of commonly prescribed drugs. The pathophysiologic process in an individual patient is often multifactorial. Diagnostic evaluation includes a focused history taking, targeted physical examination, and urinalysis. Selected patients should have a post-void residual determination, and some should undergo cystoscopy (such as those with hematuria) or complex urodynamic testing (such as those with urinary retention or neurologic disorders).
Patients with overactive bladder often benefit from supportive measures such as education, changes in fluid intake, and the use of bedside commodes or urinals, especially at night. Behavioral treatments such as pelvic-muscle exercises and bladder training are efficacious and can enhance the benefits of drug therapy. The mainstay of drug therapy is antimuscarinic agents. The two best-studied agents are oxybutynin and tolterodine; both have well-proven efficacy in short- and long-acting forms. The extended-release formulations and the oxybutynin skin patch are generally well tolerated, but all antimuscarinic drugs can have bothersome anticholinergic side effects. The effects of these agents on cognitive function are a particular concern in older adults. Men with symptoms of overactive bladder in association with benign prostatic hyperplasia may benefit from treatment with alpha-blockers. Promising future directions in drug therapy include the development of more specific antimuscarinic agents, new drug-delivery systems, and drugs that affect the sensory innervation of the lower urinary tract.
Source Information
From the Division of Geriatric Medicine and Gerontology, Wesley Woods Center, Center for Health in Aging, Emory University, and the Birmingham/Atlanta Veterans Affairs Geriatric Research Education Clinical Center — both in Atlanta.
Address reprint requests to Dr. Ouslander at the Wesley Woods Center of Emory University, 1841 Clifton Rd., NE, Atlanta, GA 30329, or at jouslan@emory.edu.
References
Abrams P, Wein AJ, eds. The Overactive Bladder: From Basic Science to Clinical Management Consensus Conference. Urology 1997;50:Suppl:1-114.
Abrams P, Wein AJ, eds. Overactive Bladder and Its Treatments Consensus Conference. Urology 2000;55:Suppl:1-84.
Staskin DR, Wein AJ, eds. New perspectives on the overactive bladder. Urology 2002;60:Suppl:1-104.
Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178.
van Kerrebroeck P, Abrams P, Chaikin D, et al. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:179-183.
Blaivas JG. Overactive bladder revisited. Neurourol Urodyn 2002;21:523-523.
Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002.
Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity: a review of the evidence regarding the long-term outcome of the overactive bladder. J Urol 2003;169:843-848.
Milson I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-766.
Stewart W, Herzog R, Wein A, et al. Prevalence and impact of overactive bladder in the US: results for the NOBLE program. Neurourol Urodyn 2001;20:406-406. abstract.
Kobelt G. Economic considerations and outcome measurement in urge incontinence. Urology 1997;50:Suppl:100-110.
Brown JS, Posner SF, Stewart AL. Urge incontinence: new health-related quality of life measures. J Am Geriatr Soc 1999;47:980-988.
DuBeau CE, Kiely DK, Resnick NM. Quality of life impact of urge incontinence in older persons: a new measure and conceptual structure. J Am Geriatr Soc 1999;47:989-994.
Dugan E, Cohen SJ, Bland DR, et al. The association of depressive symptoms and urinary incontinence among older adults. J Am Geriatr Soc 2000;48:413-416.
Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000;48:721-725.
Hu T-W. Moore K, Subak L, et al. Economics of incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:3-20.
Fisser AJ, Walmsley K, Blaivas JG. Urodynamic classification of patients with symptoms of overactive bladder. J Urol 2003;169:529-534.
Brading AF. A myogenic basis for the overactive bladder. Urology 1997;50:Suppl:57-73.
Resnick NM, Yalla SV. Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA 1987;257:3076-3081.
Morrison J, Steers WD, Brading AF, et al. Neurophysiology and neuropharmacology. In: Abrams P, Cardoza L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:86-163.
Yoshimura N, Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol 2002;168:1897-1913.
Andersson KE, Hedlund P. Pharmacologic perspective on the physiology of the lower urinary tract. Urology 2002;605:Suppl 1:13-21.
Hedge S, Choppin A, Bonhaus D, et al. Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol 1997;120:1409-1418.
Elbadawi A, Hailemariam S, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. VI. Validation and update of diagnostic criteria in 71 detrusor biopsies. J Urol 1997;157:1802-1813.
Elbadawi A, Hailemariam S, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. VII. Prospective ultrastructural/urodynamic evaluation of its natural evolution. J Urol 1997;157:1814-1822.
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. I. Methods of a prospective ultrastructural/urodynamic study and an overview of the findings. J Urol 1993;150:1650-1656.
Elbadawi A, Yalla SV, Resnick NM. Structural basis of geriatric voiding dysfunction. II. Aging detrusor: normal versus impaired contractility. J Urol 1993;150:1657-1667.
Tse V, Wills E, Szonyi G, Khadra MH. The application of ultrastructural studies in the diagnosis of bladder dysfunction in a clinical setting. J Urol 2000;163:535-539.
Jung SY, Fraser MO, Ozawa H, et al. Urethral afferent nerve activity affects the micturition reflex: implication for the relationship between stress incontinence and detrusor instability. J Urol 1999;162:204-212.
Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-825.
O'Reilly BA, Kosaka AH, Knight GF, et al. P2X receptors and their role in female idiopathic detrusor instability. J Urol 2002;167:157-164.
Fantl JA, Newman DK, Colling J, et al. Urinary incontinence in adults: acute and chronic management. Clinical practice guideline. No. 2. 1996 update. Rockville, Md.: Agency for Health Care Policy and Research, March 1996. (AHCPR publication no. 96-0682.)
McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical practice guide. No. 8. Rockville, Md.: Agency for Health Care Policy and Research, February 1994. (AHCPR publication no. 94-0582.)
Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992;148:1549-57, 1564.
Peters TJ, Donovan JL, Kay HE, et al. The International Continence Society "Benign Prostatic Hyperplasia" Study: the bothersomeness of urinary symptoms. J Urol 1997;157:885-889.
Graham CW, Dmochowki RR. Questionnaires for women with urinary symptoms. Neurourol Urodyn 2002;21:473-481.
Wyman JF, Choi SC, Harkins SW, Wilson MS, Fantl JA. The urinary diary in evaluation of incontinent women: a test-retest analysis. Obstet Gynecol 1988;71:812-817.
Locher JL, Goode PS, Roth DL, Worrell RL, Burgio KL. Reliability assessment of the bladder diary for urinary incontinence in older women. J Gerontol A Biol Sci Med Sci 2001;56:M32-M35.
Marks LS, Dorey FJ, Macairan ML, Park C, deKernion JB. Three-dimensional ultrasound device for rapid determination of bladder volume. Urology 1997;50:341-348.
DuBeau CE, Yalla SV, Resnick NM. Improving the utility of urine flow rate to exclude outlet obstruction in men with voiding symptoms. J Am Geriatr Soc 1998;46:1118-1124.
Fantl JA, Wyman JF, McClish DK, et al. Efficacy of bladder training in older women with urinary incontinence. JAMA 1991;265:609-613.
Burgio KL, Goode PS, Locher JL, et al. Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial. JAMA 2002;288:2293-2299.
Burgio KL, Locher JL, Goode PS, et al. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA 1998;280:1995-2000.
Ouslander JG, Schnelle JF, Uman G, et al. Predictors of successful prompted voiding among incontinent nursing home residents. JAMA 1995;273:1366-1370.
Johnson TM II, Kincade JE, Bernard SL, Busby-Whitehead J, DeFriese GH. Self-care practices used by older men and women to manage urinary incontinence: results from the National Follow-up Survey on Self-Care and Aging. J Am Geriatr Soc 2000;48:894-902.
Johnson TM, Ouslander JG, Uman GC, Schnelle JF. Urinary incontinence treatment preferences in long-term care. J Am Geriatr Soc 2001;49:710-718.
Brubaker L. Electrical stimulation in overactive bladder. Urology 2000;55:Suppl:17-23, 31.
Hohenfellner M, Dahms SE, Matzel K, Thuroff JW. Sacral neuromodulation for treatment of lower urinary tract dysfunction. BJU Int 2000;85:Suppl 3:10-9, 22.
Madersbacher H. Denervation techniques. BJU Int 2000;85:Suppl 3:1-6, 8.
Atala A. New methods of bladder augmentation. BJU Int 2000;85:Suppl 3:24-34, 36.
Anderson K-E, Appell R, Awad S, et al. Pharmacologic treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:481-511.
Blaivas JG, Appell RA, Fantl JA, et al. Standards of efficacy for evaluation of treatment outcomes in urinary incontinence: recommendations of the Urodynamic Society. Neurourol Urodyn 1997;16:145-147.
Fonda D, Resnick NM, Colling J, et al. Outcome measures for research of lower urinary tract dysfunction in frail older people. Neurourol Urodyn 1998;17:273-281.
Payne C, van Kerrebroeck P, Blaivas JG, et al. Research methodology in urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A, eds. Incontinence. 2nd ed. Plymouth, England: Health Publications, 2002:1047-77.
De Ridder D, Chandiramani V, Dasgupta P, Van Poppel H, Baert L, Fowler C. Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: a dual center study with long-term followup. J Urol 1997;158:2087-2092.
Levels of evidence and grades of recommendation. Oxford, England: Centre for Evidence-Based Medicine. (Accessed January 27, 2004, at http://www.cebm.net/levels_of_evidence.asp.)
Herbison P, Hay-Smith J, Ellis G, Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2003;326:841-844.
Edwards KR, O'Connor JT. Risk of delirium with concomitant use of tolterodine and acetylcholinesterase inhibitors. J Am Geriatr Soc 2002;50:1165-1166.
Katz IR, Sands LP, Bilker W, DiFillipo S, Boyce A, D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998;46:8-13.
Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-644.
Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-262.
Gupta SK, Sathyan G. Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol 1999;39:289-296.
Anderson RU, Mobley D, Blank B, Saltzstein D, Susset J, Brown JS. Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. J Urol 1999;161:1809-1812.
Gleason DM, Susset J, White C, Munoz DR, Sand PK. Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Urology 1999;54:420-423.
Birns J, Lukkari E, Malone-Lee JG. A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int 2000;85:793-798.
Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc 2001;76:358-363.
Davila GW, Daugherty CA, Sanders SW. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001;166:140-145.
Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002;168:580-586.
Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998;81:801-810.
Jonas U, Hofner K, Madersbacher H, Holmdahl TH. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. World J Urol 1997;15:144-151.
Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-289.
Freedman S, Mitcheson HD, Antoci J, Primus G, Chancellor MF, Wein A. Tolterodine, an effective and well tolerated treatment for urge incontinence and other overactive bladder symptoms. Clin Drug Invest 2000;19:83-91.
Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 2001;57:414-421.
Malone-Lee J, Shaffu B, Anand C, Powell C. Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. J Urol 2001;165:1452-1456.
Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-705.
Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807.
Sussman D, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin 2002;18:177-184.
Ouslander J, Maloney C, Grasela T, Rogers L, Walawander C. Implementation of a nursing home urinary incontinence management program with and without tolterodine. J Am Med Dir Assoc 2001;2:207-214.
Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc 2003;78:687-695.
Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000;48:370-374.
Ouslander JG, Schnelle JF, Uman G, et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 1995;43:610-617.
Mattiasson A, Blaakaer J, H?ye K, Wein AJ, Tolterodine Scandinavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder. BJU Int 2003;91:54-60.
Mazur D, Wehnert J, Dorschner W, Schubert G, Herfurth G, Alken RG. Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence: a multicentre dose-optimizing study. Scand J Urol Nephrol 1995;29:289-294.
Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner K. A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int 1999;84:646-651.
Madersbacher H, Murtz G. Efficacy, tolerability and safety profile in propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urol 2001;19:324-335.
Madersbacher H, Stohrer M, Richter R, Burgdorfer H, Hachen HJ, Murtz G. Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia. Br J Urol 1995;75:452-456.
Holmes DM, Montz FJ, Stanton SL. Oxybutynin versus propantheline in the management of detrusor instability: a patient-regulated variable dose trial. Br J Obstet Gynaecol 1989;96:607-612.
Thuroff J, Bunke B, Ebner A, et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J Urol 1991;145:813-817.
Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis: first report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1994;83:12-18.
Sultana CJ, Walters MD. Estrogen and urinary incontinence in women. Maturitas 1994;20:129-138.
Fantl JA, Bump RC, Robinson D, McClish DK, Wyman JF. Efficacy of estrogen supplementation in the treatment of urinary incontinence: the Continence Program for Women Research Group. Obstet Gynecol 1996;88:745-749.
Ouslander JG, Greendale GA, Uman G, Lee C, Paul W, Schnele J. Effects of oral estrogen and progestin on the lower urinary tract among female nursing home residents. J Am Geriatr Soc 2001;49:803-807.
Oesterling JE. Benign prostatic hyperplasia: medical and minimally invasive treatment options. N Engl J Med 1995;332:99-109.
DuBeau CE, Yalla SV, Resnick NM. Implications of the most bothersome prostatism symptom for clinical care and outcomes research. J Am Geriatr Soc 1995;43:985-992.
Thomas AW, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000;85:Suppl 3:57-68, 70.
Debruyne FM, Witjes WP, Fitzpatrick J, Kirby R, Kirk D, Prezioso D. The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1996;30:369-376.
Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.
Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. J Urol 1997;157:525-530.
Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 1998;160:1358-1367.
Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003;92:257-261.
Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001;58:717-722.
Johnson TM II, Jones K, Williford WO, Kutner MH, Issa MM, Lepor H. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial. J Urol 2003;170:145-148.
Weiss JP, Blaivas JG. Nocturia. J Urol 2000;163:5-12.
Miller M. Nocturnal polyuria in older people: pathophysiology and clinical implications. J Am Geriatr Soc 2000;48:1321-1329.
Asplund R, Aberg H. Diurnal variation in the levels of antidiuretic hormone in the elderly. J Intern Med 1991;229:131-134.
Asplund R, Aberg H. Desmopressin in elderly subjects with increased nocturnal diuresis: a two-month treatment study. Scand J Urol Nephrol 1993;27:77-82.
Ouslander JG, Nasr SZ, Miller M, et al. Arginine vasopressin levels in nursing home residents with nighttime urinary incontinence. J Am Geriatr Soc 1998;46:1274-1279.
Johnson TM II, Miller M, Pillion DJ, Ouslander JG. Arginine vasopressin and nocturnal polyuria in older adults with frequent nighttime voiding. J Urol 2003;170:480-484.
Lose G, Lalos O, Freedman RM, van Kerrebroeck P, Nocturia Study Group. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 2003;189:1106-1113.
Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J. Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 2002;89:855-862.
Smith CP, Franks ME, Phelan MW, et al. Botulinum toxin A: physiologic and clinical effects on the lower urinary tract. J Urol 2001;165:Suppl:37-37. abstract.
Schurch B, Stohrer M, Kramer G, Schmid D, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-697.
Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989;141:1350-1352.
Martin SW, Radley SC, Chess-Williams R, Korstanje C, Chapple CR. Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle. Br J Urol 1997;80:405-413.
Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000;40:161-167.
Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways to treat the overactive bladder. J Urol 1999;162:3-11.
Silva C, Ribeiro MJ, Cruz F. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fiber input. J Urol 2002;168:575-579.(Joseph G. Ouslander, M.D.)